DARE (Dare Bioscience) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DARE Dare Bioscience Inc DARE
28 GF Score
Price $0.81
GF Value $2.38
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Dare Bioscience Net Loan?

Net Loan only applies to banks and insurance companies.

DARE
28GF Score
Dare Bioscience Inc DARE
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dare Bioscience (DARE) Overvalued in 2026?

Based on GuruFocus' analysis, Dare Bioscience stock appears to be undervalued. The current stock price of $0.81 is trading 66% below its estimated GF Value™ of $2.38. GuruFocus considers Dare Bioscience to be Possible Value Trap.

Key valuation signals for DARE:

  • Net Loan:
  • GF Value™: $2.38 vs. price of $0.81 (66% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the DARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dare Bioscience Business Description

Address 3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
28GF Score

Get the complete analysis for DARE

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price
$2.38
GF Value